Lunai Bioworks Inc. Common Stock
$2.33
$0.06 (+2.42%)
$2.26Day Range$2.36
Key Statistics
Market Cap
$10.31M
Shares Outstanding
4.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 18, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$2.27
Day High
$2.36
Day Low
$2.26
Volume
16.7K
VWAP
$2.30
Prev Close
$2.27
Transactions
--
Acc. Volume
--
About Lunai Bioworks Inc. Common Stock
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
PHARMACEUTICAL PREPARATIONSSIC 283429 employeesCENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES, CA, 9006745 39179840IPO Nov 18, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001527728
- Composite FIGI
- BBG0060CNMG8
- Share Class FIGI
- BBG0060CNMH7
- Ticker Root
- LNAI
- SIC Code
- 2834
About Lunai Bioworks Inc. Common Stock (LNAI) Stock
Lunai Bioworks Inc. Common Stock (LNAI) closed the 2026-09-18 session at $2.33, up 2.42% versus the previous close (+0.06). The stock opened at $2.27 and traded between $2.26 and $2.36 during that session. Session trading volume was 17K shares. The volume-weighted average price (VWAP) is $2.30.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Lunai Bioworks Inc. Common Stock has a market capitalization of $10.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. LNAI is listed on the XNAS exchange. The company employs approximately 29 people. Lunai Bioworks Inc. Common Stock is headquartered in SUITE 906 LOS ANGELES, CA. The recorded listing date is 2014-11-18.
On this page you can find market LNAI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.